Cat. No.: HY-B1743

Puromycin

(Synonyms: CL13900)

398 Cited Publications

Avis client

Based on 398 publication(s) in Google Scholar

Puromycin dihydrochloride is the dihydrochloride salt of puromycin. Puromycin is an aminoglycoside antibiotic that inhibits protein synthesis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.55%
CAS No.: 53-79-2
Formule: C₂₂H₂₉N₇O₅
Masse moléculaire:471.51

Stockage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Puromycin Chemical Structure

CAS No.: 53-79-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (398)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Puromycin dihydrochloride is the dihydrochloride salt of puromycin. Puromycin is an aminoglycoside antibiotic that inhibits protein synthesis.

IC₅₀ & Target

Aminoglycoside

Voir tous les produits spécifiques à Isoform Antibiotic :

Voir tous les produits spécifiques à Isoform Parasite :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.6 μM Compound: Puromycin	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 27089214]
A549	IC₅₀	300 nM Compound: 5	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs	[PMID: 30418763]
BEAS-2B	IC₅₀	0.74 μM Compound: Puro	Cytotoxicity against human BEAS-2B cells with low TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human BEAS-2B cells with low TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36855911]
HCT-8	EC₅₀	6.1 μM Compound: Puromycin	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 29469575]
HEK293	IC₅₀	0.42 μM Compound: Puromycin	Cytotoxicity against HEK239 cells after 72 hrs by Alamar blue assay Cytotoxicity against HEK239 cells after 72 hrs by Alamar blue assay	[PMID: 20558060]
HEK293	IC₅₀	0.361 μM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as cell viability after 72 hrs by resazurin-based plate reader analysis Cytotoxicity against HEK293 cells assessed as cell viability after 72 hrs by resazurin-based plate reader analysis	[PMID: 26651537]
HEK293	IC₅₀	350.5 nM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as growth inhibition after 72 hrs by alamar blue viability assay Cytotoxicity against HEK293 cells assessed as growth inhibition after 72 hrs by alamar blue viability assay	[PMID: 27060763]
HEK293	IC₅₀	0.35 nM Compound: Puromycin	Cytotoxicity against HEK293 cells by alamar blue assay Cytotoxicity against HEK293 cells by alamar blue assay	[PMID: 27212070]
HEK293	IC₅₀	0.36 μM Compound: Puromycin	Growth inhibition of HEK293 cells after 72 hrs by PrestoBlue staining based fluorescence assay Growth inhibition of HEK293 cells after 72 hrs by PrestoBlue staining based fluorescence assay	[PMID: 28001067]
HEK293	IC₅₀	0.399 μM Compound: Puromycin	Growth inhibition of HEK293 cells Growth inhibition of HEK293 cells	[PMID: 28400231]
HEK293	IC₅₀	0.46 μM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by Alamar blue assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by Alamar blue assay	[PMID: 28774427]
HEK293	IC₅₀	0.45 μM Compound: Puromycin	Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay	[PMID: 29236492]
HEK293	IC₅₀	0.46 μM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as inhibition of cell growth after 72 hrs by alamar blue assay Cytotoxicity against HEK293 cells assessed as inhibition of cell growth after 72 hrs by alamar blue assay	[PMID: 29533611]
HEK293	IC₅₀	0.4 μM Compound: Puromycin	Cytotoxicity against human HEK293 cells after 72 hrs by resazurin dye based fluorescence assay Cytotoxicity against human HEK293 cells after 72 hrs by resazurin dye based fluorescence assay	[PMID: 29969262]
HEK293	CC₅₀	500.1 nM Compound: Puromycin	Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay	[PMID: 30537832]
HEK293	IC₅₀	0.694 μM Compound: Puromycin	Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye-based fluorescence assay Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye-based fluorescence assay	[PMID: 30865443]
HEK293	IC₅₀	0.36 μM Compound: Puromycin	Cytotoxicity against HEK293 cells Cytotoxicity against HEK293 cells	[PMID: 32067457]
HEK293	IC₅₀	0.81 μM Compound: Puromycin	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 33105995]
HEK293	CC₅₀	0.23 μM Compound: Puromycin	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by resazurin assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by resazurin assay	[PMID: 33479668]
HEK293	IC₅₀	0.6645 μM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue dye based fluorescence assay Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue dye based fluorescence assay	[PMID: 36799121]
HEK293	IC₅₀	837 nM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 72 hrs by resazurin dye based fluorescence assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 72 hrs by resazurin dye based fluorescence assay	[PMID: 37610242]
HEK293	IC₅₀	0.49 μM Compound: Puromycin	Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability measured after 66 hrs by Alamar Blue dye based fluorescence analysis Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability measured after 66 hrs by Alamar Blue dye based fluorescence analysis	[PMID: 38416027]
HEK-293T	CC₅₀	0.42 μM Compound: Puromycin	Cytotoxicity against human HEK293T cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay Cytotoxicity against human HEK293T cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay	[PMID: 29469575]
HEK-293T	IC₅₀	1.28 μM Compound: Puro	Cytotoxicity against human HEK293T cells with low TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HEK293T cells with low TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36855911]
HeLa	IC₅₀	0.9 μM Compound: Puro	Cytotoxicity against human HeLa cells with high TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells with high TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36855911]
Hepatocyte	CC₅₀	1.1 μM Compound: Puromycin	Cytotoxicity against human primary hepatocytes assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human primary hepatocytes assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
Hepatocyte	CC₅₀	1740 nM Compound: Puromycin	Cytotoxicity against human primary hepatocytes Cytotoxicity against human primary hepatocytes	[PMID: 38262446]
HepG2	IC₅₀	0.23 μM Compound: puromycin	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 18313307]
HepG2	IC₅₀	364 μM Compound: puromycin	Resistant ratio, IC50 for multidrug resistant human HepG2 cells to IC50 for human HepG2 cells Resistant ratio, IC50 for multidrug resistant human HepG2 cells to IC50 for human HepG2 cells	[PMID: 18313307]
HepG2	IC₅₀	83.93 μM Compound: puromycin	Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay	[PMID: 18313307]
HepG2	IC₅₀	2.1 x 10^-1 μM Compound: puromycin	Growth inhibition of human HepG2 cells after 72 hrs by SRB assay Growth inhibition of human HepG2 cells after 72 hrs by SRB assay	[PMID: 18512984]
HepG2	CC₅₀	0.83 μM Compound: Puromycin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay	[PMID: 29469575]
HepG2	IC₅₀	1.29 μM Compound: Puro	Cytotoxicity against human HepG2 cells with high TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells with high TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36855911]
HepG2	CC₅₀	0.78 μM Compound: Puromycin	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
HepG2	CC₅₀	398 nM Compound: Puromycin	Cytotoxicity against human HepG2 cells incubated for 72 hrs by Hoechst 33342 staining based assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by Hoechst 33342 staining based assay	[PMID: 38262446]
HL-60	EC₅₀	0.055 μM Compound: 1	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 28803047]
HL-60	IC₅₀	3.73 μM Compound: Puro	Cytotoxicity against human HL-60 cells with low TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HL-60 cells with low TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36855911]
Huh-7	CC₅₀	6.63 μM Compound: GNF-Pf-2016	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
Huh-7	CC₅₀	0.43 μM Compound: Puromycin	Cytotoxicity against human Huh-7 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
J774.A1	IC₅₀	10 μM Compound: Puromycin	Cytotoxicity against mouse J774A1 cells by trypan blue exclusion assay Cytotoxicity against mouse J774A1 cells by trypan blue exclusion assay	[PMID: 22934636]
K562	IC₅₀	0.22 μM Compound: puromycin	Growth inhibition of human K562 cells after 72 hrs by SRB assay Growth inhibition of human K562 cells after 72 hrs by SRB assay	[PMID: 18313307]
K562	IC₅₀	122 μM Compound: puromycin	Resistant ratio, IC50 for multidrug resistant human K562 cells to IC50 for human K562 cells Resistant ratio, IC50 for multidrug resistant human K562 cells to IC50 for human K562 cells	[PMID: 18313307]
K562	IC₅₀	26.83 μM Compound: puromycin	Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay	[PMID: 18313307]
KB 3-1	IC₅₀	0.21 μM Compound: puromycin	Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay	[PMID: 18313307]
KB 3-1	IC₅₀	378 μM Compound: puromycin	Resistant ratio, IC50 for multidrug resistant human KB3-1 cells to IC50 for human KB3-1 cells Resistant ratio, IC50 for multidrug resistant human KB3-1 cells to IC50 for human KB3-1 cells	[PMID: 18313307]
KB-V1	IC₅₀	79.3 μM Compound: puromycin	Growth inhibition of human KB V1 cells after 72 hrs by MTT assay Growth inhibition of human KB V1 cells after 72 hrs by MTT assay	[PMID: 18313307]
MCF7	IC₅₀	1.06 μM Compound: Puro	Cytotoxicity against human MCF7 cells with low TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells with low TrxR expression assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36855911]
MDA-MB-231	CC₅₀	0.48 μM Compound: Puromycin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 28523103]
MIA PaCa-2	CC₅₀	0.2 μM Compound: Puromycin	Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 28523103]
MOLT-4	EC₅₀	0.17 μM Compound: 1	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 28803047]
MRC5	CC₅₀	0.32 μM Compound: Puromycin	Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
MT4	CC₅₀	0.12 μM Compound: Puromycin	Cytotoxicity against human MT4 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
P388	IC₅₀	0.5 μg/mL Compound: Puromycin	Cytotoxicity against P388 mouse leukemia cells Cytotoxicity against P388 mouse leukemia cells	[PMID: 1433208]
PBMC	CC₅₀	1.1 μM Compound: Puromycin	Cytotoxicity against stimulated human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against stimulated human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PBMC	CC₅₀	5.05 μM Compound: Puromycin	Cytotoxicity against quiescent human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against quiescent human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PC-3	IC₅₀	0.7 μM Compound: Puromycin	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 27089214]
PC-3	IC₅₀	300 nM Compound: 5	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs	[PMID: 30418763]
PC-3	CC₅₀	0.47 μM Compound: Puromycin	Cytotoxicity against human PC-3 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human PC-3 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
SU-DHL10	CC₅₀	0.11 μM Compound: Puromycin	Cytotoxicity against human SU-DHL10 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay Cytotoxicity against human SU-DHL10 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 28523103]
Vero	CC₅₀	2.8 μM Compound: 1	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell proliferation after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell proliferation after 72 hrs by MTT assay	[PMID: 28803047]
Vero	CC₅₀	2.76 μM Compound: 3	Cytotoxicity against African green monkey Vero cells by MTT assay Cytotoxicity against African green monkey Vero cells by MTT assay	[PMID: 38917665]

In Vitro

Puromycin blocks protein synthesis after aminoacyl-sRNA formation, and at the same time it leads to the accumulation of small peptides. Both of these effects appear to be due to the splitting of ribosome-bound peptidyl-sRNA,4 which results in release of incomplete peptide chains.^[1]. Puromycin, an analog of the 3' end of aminoacyl-tRNA, causes premature termination of translation by being linked non-specifically to growing polypeptide chains. Puromycin has two modes of inhibitory action. The first is by acting as an acceptor substrate which attacks peptidyl-tRNA in the P site to form a nascent peptide. The second is by competing with aminoacyl-tRNA for binding to the A' site^[2]. When used in minimal amounts, puromycin incorporation in neosynthesized proteins reflects directly the rate of mRNA translation in vitro. Puromycin immunodetection is an advantageous alternative to radioactive amino acid labeling. It allows the direct evaluation of translation activity in single cells by immunofluorescence microscopy and in heterogenous populations of cells by fluorescenceactivated cell sorting^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 53-79-2
Appearance Solid
Masse moléculaire 471.51
Formule C₂₂H₂₉N₇O₅
Color White to off-white
SMILES

OC[C@@H]1[C@@H](NC([C@@H](N)CC2=CC=C(OC)C=C2)=O)[C@H]([C@H](N3C=NC4=C3N=CN=C4N(C)C)O1)O
Synonyms

CL13900
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
- Microorganisms
Streptomyces alboniger
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (398)

All OthersIFWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Macrophages promote pre-metastatic niche formation of breast cancer through aryl hydrocarbon receptor activity. [Abstract]

2024 Dec 18;9(1):352. PMID: 39690159
Signal Transduct Target Ther

Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. [Abstract]

2022 Feb 28;7(1):54. PMID: 35221331
Science

Hydrolytic endonucleolytic ribozyme (HYER) is programmable for sequence-specific DNA cleavage. [Abstract]

2024 Feb 2;383(6682):eadh4859. PMID: 38301022
J Hematol Oncol

YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma. [Abstract]

2021 Jul 10;14(1):109. PMID: 34246306
Mol Cancer

Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. [Abstract]

2024 May 6;23(1):90. PMID: 38711083
Mol Cancer

WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. [Abstract]

2019 Aug 22;18(1):127. PMID: 31438961
Cell Metab

Liver-breast communication of adipocyte-oriented exosomes drives primary mammary cancer progression. [Abstract]

2025 Sep 24:S1550-4131(25)00385-7. PMID: 40997802
Cell Metab

Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. [Abstract]

2025 Sep 2;37(9):1907-1925.e14. PMID: 40803319
Nat Genet

Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations. [Abstract]

2025 Dec 8. PMID: 41361008
Adv Mater

Ultrathin Hydrogel Films Toward Breathable Skin-Integrated Electronics. [Abstract]

2023 Jan;35(1):e2206793. PMID: 36267034
Nat Biomed Eng

2026 Jan 7.
Cancer Commun (Lond)

NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway. [Abstract]

2025 Jun 20. PMID: 40540648
Cancer Commun (Lond)

Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality. [Abstract]

2023 Jan;43(1):123-149. PMID: 36353796
Drug Resist Updat

MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance. [Abstract]

2025 Apr 17:81:101246. PMID: 40262414
Sci Bull

Genetically engineered MSCs overexpressing hepatocyte growth factor for the treatment of human refractory wounds. [Abstract]

2025 Nov 25:S2095-9273(25)01198-3. PMID: 41381331
Nat Metab

NK cell-derived IFNγ mobilizes free fatty acids from adipose tissue to promote early B cell activation during viral infection. [Abstract]

2025 Apr 11. PMID: 40217117
Bioact Mater

Dominant role of in situ native cartilage niche for determining the cartilage type regenerated by BMSCs. [Abstract]

2021 Nov 12:13:149-160. PMID: 35224298
Cell Mol Immunol

Lkb1 orchestrates γδ T-cell metabolic and functional fitness to control IL-17-mediated autoimmune hepatitis. [Abstract]

2024 Jun;21(6):546-560. PMID: 38641698
Nat Aging

Mitochondria-associated condensates maintain mitochondrial homeostasis and promote lifespan. [Abstract]

2025 Sep 10. PMID: 40931112
Adv Funct Mater

2019, 1808556.
Cancer Res

NSD1-Mediated PPARγ Methylation Enhances PTEN Activity to Suppress Glycolysis and Tumor Progression in Endometrial Cancer. [Abstract]

2026 Mar 2. PMID: 41770031
Mol Cell

Nuclear retention coupled with sequential polyadenylation dictates post-transcriptional m6A modification in the nucleus. [Abstract]

2024 Aug 1:S1097-2765(24)00593-8. PMID: 39127036
Mol Cell

m6A modification negatively regulates translation by switching mRNA from polysome to P-body via IGF2BP3. [Abstract]

2023 Dec 21;83(24):4494-4508.e6. PMID: 38016476

Puromycin purchased from MedChemExpress. Usage Cited in: Mol Cell. 2023 Dec 21;83(24):4494-4508.e6. [Abstract]

Global protein synthesis analyzed by puromycin dihydrochloride (4 d) labeling assay upon METTL14 knockdown in HeLa cells. Silencing of EIF3A serves as a positive control.

Puromycin purchased from MedChemExpress. Usage Cited in: Mol Cell. 2023 Dec 21;83(24):4494-4508.e6. [Abstract]

Global protein synthesis analyzed by puromycin dihydrochloride (4 d) labeling assay upon IGF2BP1-3 knockdown in HeLa cells.
Mol Cell

CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. [Abstract]

2023 Dec 7;83(23):4370-4385.e9. PMID: 38016475
Cancer Res

Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer. [Abstract]

2023 Jul 5;83(13):2187-2207. PMID: 37061993
Sci Immunol

Radiotherapy enhances anticancer CD8 T cell responses by cGAMP transfer through LRRC8A/C volume-regulated anion channels. [Abstract]

2025 Jun 27;10(108):eadn1630. PMID: 40577443
Nat Protoc

Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states. [Abstract]

2025 Oct 8. PMID: 41062702
Hepatology

An Endoplasmic Reticulum Stress-MicroRNA-26a Feedback Circuit in NAFLD. [Abstract]

2021 Apr;73(4):1327-1345. PMID: 32567701
Nat Commun

Diet-induced RKIP downregulation disrupts PC/PE-ER homeostasis to drive MASLD. [Abstract]

2025 Dec 12;16(1):11092. PMID: 41387436
Nat Commun

VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization. [Abstract]

2025 Oct 10;16(1):9027. PMID: 41073389
Nat Commun

Photoswitchable intein for light control of covalent protein binding and cleavage. [Abstract]

2025 Sep 11;16(1):8263. PMID: 40935816
Nat Commun

RIPK1 kinase drove brain microvascular endothelial cells death and blood-brain barrier disruption in neonatal Escherichia coli meningitis. [Abstract]

2025 Aug 7;16(1):7309. PMID: 40774959
Nat Commun

Myocardial mitochondrial antiviral signaling protein promotes heart Ischemia-reperfusion injury via RIG-I signaling in mice. [Abstract]

2025 Jun 2;16(1):5101. PMID: 40456736
Nat Commun

Deep learning prioritizes cancer mutations that alter protein nucleocytoplasmic shuttling to drive tumorigenesis. [Abstract]

2025 Mar 14;16(1):2511. PMID: 40087285
Nat Commun

The adaptor protein AP-3β disassembles heat-induced stress granules via 19S regulatory particle in Arabidopsis. [Abstract]

2025 Feb 27;16(1):2039. PMID: 40016204
Nat Commun

Nucleus-translocated GCLM promotes chemoresistance in colorectal cancer through a moonlighting function. [Abstract]

2025 Jan 2;16(1):263. PMID: 39747101
Nat Commun

AMFR-mediated Flavivirus NS2A ubiquitination subverts ER-phagy to augment viral pathogenicity. [Abstract]

2024 Nov 6;15(1):9578. PMID: 39505910

Puromycin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 6;15(1):9578. [Abstract]

Viral titers of supernatants from Huh7.0 FAM134B WT cells, Huh7.0 FAM134B KO cells, Huh7.0 FAM134B KO cells (1 μg/mL, 48 h) stably expressing FAM134BWT or Huh7.0 FAM134B KO cells stably expressing FAM134BR142A, infected with ZIKV at an MOI of 1 for 72 h, quantified by plaque assay.
Nat Commun

Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis. [Abstract]

2022 Mar 10;13(1):1248. PMID: 35273176
Nat Commun

Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. [Abstract]

2019 Dec 2;10(1):5492. PMID: 31792210
Bone Res

Enhanced SIRT3 expression restores mitochondrial quality control mechanism to reverse osteogenic impairment in type 2 diabetes mellitus. [Abstract]

2025 Mar 3;13(1):30. PMID: 40025004
Acta Pharm Sin B

2025 Dec 11.
J Extracell Vesicles

Targeted Blockage of Pathological Extracellular Vesicles and Particles From Fibroblast-Like Synoviocytes for Osteoarthritis Relief: Proteomic Analysis and Cellular Effect. [Abstract]

2025 Sep;14(9):e70162. PMID: 40919882
J Extracell Vesicles

Exomeres From Adventitial Fibroblasts of Spontaneously Hypertensive Rats Promote Vascular Remodelling via Transferring Osteopontin. [Abstract]

2025 Aug;14(8):e70146. PMID: 40767027
Autophagy

Impaired mitophagy contributes to osteogenesis and mineralization disorders in fibrous dysplasia. [Abstract]

2026 Mar 15:1-22. PMID: 41803635
Autophagy

PRKAB2 as a tumor suppressor in renal cell carcinoma: inhibiting mitophagy via the LRPPRC-PRKN/parkin interaction and cardiolipin biosynthesis. [Abstract]

2026 May;22(5):982-1002. PMID: 41612594
Autophagy

Nonreceptor tyrosine kinase ABL1 regulates lysosomal acidification by phosphorylating the ATP6V1B2 subunit of the vacuolar-type H+-ATPase. [Abstract]

2025 Jun;21(6):1192-1211. PMID: 39757940

Puromycin purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Jun;21(6):1192-1211. [Abstract]

Wild-type or mutated A549 cells subjected to the indicated treatments were stably transfected with a puromycin-inducible GFP-LC3 lentivirus at an MOI of 5. Autophagosomes levels were represented by the presence of GFP-LC3 in cells (A scale bar: 10 μm; B scale bar: 20 μm) (left panel).
Autophagy

GORASP2 promotes phagophore closure and autophagosome maturation into autolysosomes. [Abstract]

2024 Jul 26:1-17. PMID: 39056394
Autophagy

Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. [Abstract]

2021 Dec;17(12):4083-4101. PMID: 33764843
Adv Sci (Weinh)

2026 Mar;13(17):e73843. PMID: 41562200
Adv Sci (Weinh)

An Insulin-Exosome-TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer. [Abstract]

2026 Apr;13(24):e15606. PMID: 41709860
Adv Sci (Weinh)

Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. [Abstract]

2026 Apr;13(21):e18975. PMID: 41655233
Adv Sci (Weinh)

Perfluorooctanoic Acid Exposure Causes Macrophage Ammonia Retention and Induces Spontaneous Miscarriages. [Abstract]

2026 Jan 4:e06994. PMID: 41486358
Adv Sci (Weinh)

Marginal Stability of the YB1 Cold-Shock Domain in Cells Enables Binding of Multiple Nucleic Acids. [Abstract]

2025 Oct 27:e12966. PMID: 41144700
Adv Sci (Weinh)

ST6GAL1-Mediated Sialylation Stabilizes PD-L1 and Drives Immunosuppressive Tumor Microenvironment in Colorectal Cancer. [Abstract]

2025 Aug 22:e06225. PMID: 40847469
Adv Sci (Weinh)

Restoration of SIRT3 Expression in Aged Mice Alleviates UUO-Induced Renal Fibrosis by Reducing GSK-3β Hyperacetylation. [Abstract]

2025 Jul 23:e17248. PMID: 40698425
Adv Sci (Weinh)

WTAP Mediated m6A Modification Stabilizes PDIA3P1 and Promotes Tumor Progression Driven by Histone Lactylation in Esophageal Squamous Cell Carcinoma. [Abstract]

2025 Jun 5:e06529. PMID: 40470706
Adv Sci (Weinh)

Hybrid EMT Phenotype and Cell Membrane Tension Promote Colorectal Cancer Resistance to Ferroptosis. [Abstract]

2025 Feb 22:e2413882. PMID: 39985376
Adv Sci (Weinh)

Ribonuclease 1 Induces T-Cell Dysfunction and Impairs CD8+ T-Cell Cytotoxicity to Benefit Tumor Growth through Hijacking STAT1. [Abstract]

2025 Apr;12(13):e2404961. PMID: 39932384
Adv Sci (Weinh)

ShK-modified UCMSCs Inhibit M1-Like Macrophage Polarization and Alleviate Osteoarthritis Progression via PI3K/Akt Axis. [Abstract]

2024 Dec 25:e2406822. PMID: 39721037
Adv Sci (Weinh)

Lactylation of Histone H3k18 and Egr1 Promotes Endothelial Glycocalyx Degradation in Sepsis-Induced Acute Lung Injury. [Abstract]

2024 Dec 25:e2407064. PMID: 39721014
Adv Sci (Weinh)

Neuropeptide Precursor VGF Promotes Liver Metastatic Colonization of Gαq Mutant Uveal Melanoma by Facilitating Tumor Microenvironment via Paracrine Loops. [Abstract]

2024 Dec;11(46):e2407967. PMID: 39422674
Adv Sci (Weinh)

FUS Selectively Facilitates circRNAs Packing into Small Extracellular Vesicles within Hypoxia Neuron. [Abstract]

2024 Jun 26:e2404822. PMID: 38924471
Adv Sci (Weinh)

DNMT3A Cooperates with YAP/TAZ to Drive Gallbladder Cancer Metastasis. [Abstract]

2024 Apr;11(16):e2308531. PMID: 38380551
J Clin Invest

2026 May 12.
Neuro Oncol

FRK inhibits glioblastoma progression via phosphorylating YAP and inducing its ubiquitylation and degradation by Siah1. [Abstract]

2022 Dec 1;24(12):2107-2120. PMID: 35723276
Theranostics

FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells. [Abstract]

2021 Mar 5;11(10):5045-5060. PMID: 33754043
Theranostics

STIM1 is a metabolic checkpoint regulating the invasion and metastasis of hepatocellular carcinoma. [Abstract]

2020 May 16;10(14):6483-6499. PMID: 32483465
Nucleic Acids Res

THUMPD2 catalyzes the N2-methylation of U6 snRNA of the spliceosome catalytic center and regulates pre-mRNA splicing and retinal degeneration. [Abstract]

2024 Apr 12;52(6):3291-3309. PMID: 38165050
Exp Mol Med

Hypoxia-hindered methylation of PTGIS in endometrial stromal cells accelerates endometriosis progression by inducing CD16- NK-cell differentiation. [Abstract]

2022 Jul;54(7):890-905. PMID: 35781537
J Exp Clin Cancer Res

TCF3 activates super-enhancer-driven TRIB2 overexpression to suppress ferroptosis and promote hepatoblastoma proliferation. [Abstract]

2025 Dec 29;44(1):329. PMID: 41462308
J Exp Clin Cancer Res

Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer. [Abstract]

2025 Aug 19;44(1):245. PMID: 40830980
J Exp Clin Cancer Res

Viral expression of NE/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory/effector CD8+ T cell infiltration. [Abstract]

2025 Mar 14;44(1):97. PMID: 40082916
J Exp Clin Cancer Res

NONO regulates m5C modification and alternative splicing of PTEN mRNAs to drive gastric cancer progression. [Abstract]

2025 Mar 4;44(1):81. PMID: 40033337
J Exp Clin Cancer Res

PHGDH activation fuels glioblastoma progression and radioresistance via serine synthesis pathway. [Abstract]

2025 Mar 19;44(1):99. PMID: 40102981
J Exp Clin Cancer Res

MYL9 expressed in cancer-associated fibroblasts regulate the immune microenvironment of colorectal cancer and promotes tumor progression in an autocrine manner. [Abstract]

2023 Nov 6;42(1):294. PMID: 37926835
J Exp Clin Cancer Res

Gastric cancer-derived LBP promotes liver metastasis by driving intrahepatic fibrotic pre-metastatic niche formation. [Abstract]

2023 Oct 3;42(1):258. PMID: 37789385
J Exp Clin Cancer Res

PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p. [Abstract]

2022 Mar 28;41(1):111. PMID: 35346324
J Exp Clin Cancer Res

Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy. [Abstract]

2021 Nov 25;40(1):373. PMID: 34823564
J Exp Clin Cancer Res

Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers. [Abstract]

2016 Nov 7;35(1):173. PMID: 27821145
Microbiome

Role of nasal microbiota in regulating host anti-influenza immunity in dogs. [Abstract]

2025 Jan 27;13(1):27. PMID: 39871363
J Nanobiotechnology

AMFR-mediated ER-phagy regulation and therapeutic targeting in osteosarcoma: a multifunctional nanoplatform strategy. [Abstract]

2025 Nov 18;23(1):717. PMID: 41250206
Sci Adv

VIRMA-mediated m6A modification regulates forebrain formation through modulating ribosome biogenesis. [Abstract]

2025 Jun 27;11(26):eadq9643. PMID: 40577453
Cell Discov

A positive feedback loop between SMAD3 and PINK1 in regulation of mitophagy. [Abstract]

2025 Mar 11;11(1):22. PMID: 40064862
Sci Adv

Local soft niches in mechanically heterogeneous primary tumors promote brain metastasis via mechanotransduction-mediated HDAC3 activity. [Abstract]

2025 Feb 28;11(9):eadq2881. PMID: 40009679
Int J Oral Sci

Porphyromonas gingivalis potentiates stem-like properties of oral squamous cell carcinoma by modulating SCD1-dependent lipid synthesis via NOD1/KLF5 axis. [Abstract]

2025 Feb 28;17(1):15. PMID: 40016182
Metabolism

SLC22A6-dependent lactylation of H3K9 aggravates endothelial dysfunction and atherosclerosis. [Abstract]

2025 Nov 4:175:156426. PMID: 41197766
Redox Biol

Extracellular vesicle-mediated delivery of mitochondrial circRNA MTCO2 protects against cerebral ischemia by modulating mPTP-dependent ferroptosis. [Abstract]

2025 Aug 5:86:103806. PMID: 40768899
J Control Release

Metal phenolic networks-driven bufalin homodimeric prodrug nano-coassemblies for ferroptosis-augmented tumor therapy. [Abstract]

2025 Jul 10:383:113814. PMID: 40319917
Research (Wash D C)

2026 Apr 14:9:1232. PMID: 41988019
Research (Wash D C)

RBM15 Enhances 5-Fluorouracil Drug Sensitivity and Suppresses Gastric Cancer Progression by Modulating N6-Methyladenosine Modification of ECT2-Dependent IGF2BP3. [Abstract]

2026 Feb 2:9:1108. PMID: 41635511
Research (Wash D C)

Notch2 Signaling Drives Cardiac Hypertrophy by Suppressing Purine Nucleotide Metabolism. [Abstract]

2025 Mar 18:8:0635. PMID: 40104444
MedComm (2020)

Tweety homolog 3 promotes colorectal cancer progression through mutual regulation of histone deacetylase 7. [Abstract]

2024 May 31;5(6):e576. PMID: 38827027
J Immunother Cancer

Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. [Abstract]

2026 Feb 4;14(2):e012886. PMID: 41638869
J Immunother Cancer

AMPK agonism optimizes the in vivo activation and antileukemic efficacy of chimeric antigen receptor T cells. [Abstract]

2025 Dec 21;13(12):e010312. PMID: 41423271
Cell Rep Med

MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1. [Abstract]

2025 Jan 16:101922. PMID: 39842432
Diabetologia

α7 Nicotinic acetylcholine receptor activation rescues mitochondrial dysfunction in gestational diabetes mellitus by competing with p66Shc for VDAC1 binding. [Abstract]

2025 Dec 15. PMID: 41396300
Clin Cancer Res

UBE2T-mediated HP1α ubiquitination enhances nucleolar function and promotes the progression of IDH1/TP53-mutant glioma. [Abstract]

2025 Jul 8. PMID: 40627452
Cancer Lett

Hypoxia-driven phase separation of the PABP1/eIF4B complex forms stress granules and activates ChaC2 translation to promote polyunsaturated lipids-supported peritoneal metastasis in gastric cancer. [Abstract]

2026 May 1:645:218392. PMID: 41780839
Mol Biomed

Ubiquitin-specific protease 13 promotes colorectal cancer progression by stabilizing mitogen-activated protein kinase kinase 3. [Abstract]

2025 Nov 27;6(1):122. PMID: 41307804
Cancer Lett

The Actin Histidine methyltransferase SETD3 is a CHD1 lysine di-methyltransferase. [Abstract]

2025 Oct 2:218073. PMID: 41045985
Cancer Lett

FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2. [Abstract]

2024 Jun 1:591:216848. PMID: 38604312
Cancer Lett

Direct interaction of platelet with tumor cell aggravates hepatocellular carcinoma metastasis by activating TLR4/ADAM10/CX3cl1 axis. [Abstract]

2024 Mar 31:585:216674. PMID: 38280480
Cancer Lett

Deubiquitination of the repressor E2F6 by USP22 facilitates AKT activation and tumor growth in hepatocellular carcinoma. [Abstract]

2021 Oct 10:518:266-277. PMID: 34339800
Cancer Lett

METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma. [Abstract]

2021 Jul 28:511:36-46. PMID: 33933553
Cancer Lett

ARID1A-dependent permissive chromatin accessibility licenses estrogen-receptor signaling to regulate circadian rhythms genes in endometrial cancer. [Abstract]

2020 Nov 1;492:162-173. PMID: 32858102
Int J Biol Sci

2026 Jan 1.
Int J Biol Sci

SESN2 inhibits tubular exosome secretion and diabetic kidney disease progression by restoring the autophagy‒lysosome pathway. [Abstract]

2025 Jun 20;21(9):4215-4230. PMID: 40612680
Int J Biol Sci

Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer. [Abstract]

2024 Oct 14;20(14):5548-5575. PMID: 39494327
Cell Death Dis

2026 Apr 8;17(1):484. PMID: 41951577
Cell Death Dis

A new candidate tumor suppressor tRF-Ser inhibits gastric cancer progression by regulating the CNBP/HSPA8 axis. [Abstract]

2026 Mar 25;17(1):379. PMID: 41881984
Cell Death Dis

Overexpression of RUNX2 promotes breast cancer multi-organ metastasis through stabilizing c-Myc. [Abstract]

2025 Oct 6;16(1):696. PMID: 41053083
Burns Trauma

Histone lactylation exacerbates acute lung injury in septic mice by promoting ferroptosis in pulmonary microvascular endothelial cells. [Abstract]

2025 Sep 18:13:tkaf056. PMID: 41262553
Cell Death Dis

Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis. [Abstract]

2025 Jun 17;16(1):452. PMID: 40523886
Cell Death Dis

Interleukin-33 (IL-33) promotes DNA damage-resistance in lung cancer. [Abstract]

2025 Apr 11;16(1):274. PMID: 40216748
Adv Healthc Mater

CircAars-Engineered ADSCs Facilitate Maxillofacial Bone Defects Repair Via Synergistic Capability of Osteogenic Differentiation, Macrophage Polarization and Angiogenesis. [Abstract]

2025 Apr;14(10):e2404501. PMID: 40035523
Cell Death Dis

Hypoxia-triggered ERRα acetylation enhanced its oncogenic role and promoted progression of renal cell carcinoma by coordinating autophagosome-lysosome fusion. [Abstract]

2025 Jan 16;16(1):23. PMID: 39820331
Cell Death Dis

METTL3 promotes colorectal cancer progression through activating JAK1/STAT3 signaling pathway. [Abstract]

2023 Nov 25;14(11):765. PMID: 38001065
Cell Death Dis

Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer. [Abstract]

2023 Oct 6;14(10):653. PMID: 37803002
Cell Death Dis

CDK5RAP2 is a Wnt target gene and promotes stemness and progression of oral squamous cell carcinoma. [Abstract]

2023 Feb 11;14(2):107. PMID: 36774351
Cell Death Dis

MEOX2-mediated regulation of Cathepsin S promotes cell proliferation and motility in glioma. [Abstract]

2022 Apr 18;13(4):360. PMID: 35436995
Cell Death Dis

The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer. [Abstract]

2021 Oct 14;12(10):944. PMID: 34650035
Cell Death Dis

NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation. [Abstract]

2021 Sep 9;12(9):842. PMID: 34504059
Cell Death Dis

LncRNA LINC00998 inhibits the malignant glioma phenotype via the CBX3-mediated c-Met/Akt/mTOR axis. [Abstract]

2020 Dec 2;11(12):1032. PMID: 33268783
Cell Death Dis

Tenascin-cmediated vasculogenic mimicry formation via regulation of MMP2/MMP9 in glioma. [Abstract]

2019 Nov 21;10(12):879. PMID: 31754182
Sci China Life Sci

AZD1775 synergizes with SLC7A11 inhibition to promote ferroptosis. [Abstract]

2025 Jan;68(1):204-218. PMID: 39245684
Genes Dis

Microglial NFAT5 aggravates neuroinflammation via mediating NLRP6 inflammasome in experimental ischemic stroke. [Abstract]

2025 Apr 1;12(6):101614. PMID: 40831534
Proc Natl Acad Sci U S A

Stepwise activation of SARM1 for cell death and axon degeneration revealed by a biosynthetic NMN mimic. [Abstract]

2025 Feb 25;122(8):e2424906122. PMID: 39964720
Cell Commun Signal

Netrin-1-UNC5B/neogenin axis enhances the stemness of colorectal cancer cells. [Abstract]

2025 Nov 13;23(1):496. PMID: 41233873
Cell Commun Signal

NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143. [Abstract]

2022 Jun 15;20(1):87. PMID: 35705994
Int J Biol Macromol

Inhibition of voltage-dependent anion channel 1 aggregation protects pancreatic beta-cell mitochondria from glucose toxicity. [Abstract]

2026 Apr:356:151598. PMID: 41871761
Int J Biol Macromol

The CFP macromolecule attenuates senescent liver sinusoidal endothelial cell-driven activation of hepatic stellate cells. [Abstract]

2026 Mar:350:150930. PMID: 41698486
Int J Biol Macromol

Unveiling the mechanistic link between peroxiredoxin inhibition and ferroptosis-like cell death induced by Dinaciclib in Entamoeba histolytica. [Abstract]

2026 Mar:350:150992. PMID: 41713546
Int J Biol Macromol

Exosomal microRNA-20b-5p contributes to cytarabine resistance in acute myeloid leukemia via the microtubule-associated serine/threonine kinase-like-phosphatidylinositol 3-kinase-protein kinase B signaling axis. [Abstract]

2025 Dec;333(Pt 2):148750. PMID: 41197693
Int J Biol Macromol

CircEGLN1 alleviates calcium oxalate-induced renal injury via miR-212-5p/STARD7 axis, offering a potential strategy for kidney stone prevention. [Abstract]

2025 Sep;321(Pt 1):145938. PMID: 40685053
Int J Biol Macromol

HDAC3 and Snail2 complex promotes melanoma metastasis by epigenetic repression of IGFBP3. [Abstract]

2025 Jan 24:140310. PMID: 39864688
Int J Biol Macromol

Role of ionizing radiation activated NRF2 in lung cancer radioresistance. [Abstract]

2023 Jun 30:241:124476. PMID: 37076059
Acta Pharmacol Sin

eIF4A1 exacerbates myocardial ischemia-reperfusion injury in mice by promoting nuclear translocation of transgelin/p53. [Abstract]

2025 May;46(5):1236-1249. PMID: 39856433
Acta Pharmacol Sin

Proteasomal inhibitors induce myeloma cell pyroptosis via the BAX/GSDME pathway. [Abstract]

2023 Jul;44(7):1464-1474. PMID: 36807412
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Phytomedicine

β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis. [Abstract]

2023 Jun:114:154769. PMID: 36940580
Cancer Immunol Res

KRT17 promotes T-lymphocyte infiltration through the YTHDF2-CXCL10 axis in colorectal cancer. [Abstract]

2023 Jul 5;11(7):875-894. PMID: 37129929
Cancer Immunol Res

Netrin-1 promotes the immunosuppressive activity of MDSCs in colorectal cancer. [Abstract]

2023 May 3;11(5):600-613. PMID: 36812256
NPJ Precis Oncol

NDUFA4L2 regulates the progression and chemotherapy sensitivity of HNSCC by inhibiting PANoptosis. [Abstract]

2026 Mar 5;10(1):154. PMID: 41787028
NPJ Precis Oncol

RICH1 enhances pro-inflammatory TAM infiltration in breast cancer via promoting TRIM21-mediated ubiquitination of RhoA and inhibiting STAT3 phosphorylation. [Abstract]

2025 Dec 23. PMID: 41436617
NPJ Precis Oncol

FOXA1-dependent NSUN2 facilitates the advancement of prostate cancer by preserving TRIM28 mRNA stability in a m5C-dependent manner. [Abstract]

2025 May 3;9(1):127. PMID: 40319192
NPJ Precis Oncol

SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis. [Abstract]

2024 Mar 1;8(1):58. PMID: 38429411
Biodes Manuf

2022 Apr 18.
Biodes Manuf

03 March 2022.
J Transl Med

RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway. [Abstract]

2024 Nov 22;22(1):1052. PMID: 39574120
J Transl Med

KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner. [Abstract]

2024 Jun 20;22(1):584. PMID: 38902717
J Transl Med

UBXN1 promotes liver tumorigenesis by regulating mitochondrial homeostasis. [Abstract]

2024 May 21;22(1):485. PMID: 38773518
Biomed Pharmacother

CA8 promotes RCC proliferation and migration though its expression level is lower in tumor compared to adjacent normal tissue. [Abstract]

2020 Jan;121:109578. PMID: 31715371
Oncogene

Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade. [Abstract]

2025 Oct 11. PMID: 41076461
Stem Cell Res Ther

Knockout of B2M in combination with PD-L1 overexpression protects MSC-derived new islet β cells from graft rejection in the treatment of canine diabetes mellitus. [Abstract]

2024 Dec 2;15(1):458. PMID: 39623490
Oncogene

NSUN2 regulates Wnt signaling pathway depending on the m5C RNA modification to promote the progression of hepatocellular carcinoma. [Abstract]

2024 Nov;43(47):3469-3482. PMID: 39375506
Oncogene

FBXO28 suppresses liver cancer invasion and metastasis by promoting PKA-dependent SNAI2 degradation. [Abstract]

2023 Sep;42(39):2878-2891. PMID: 37596321
Oncogene

The keratin 17/YAP/IL6 axis contributes to E-cadherin loss and aggressiveness of diffuse gastric cancer. [Abstract]

2022 Feb;41(6):770-781. PMID: 34845376
Cell Death Discov

UCHL1 stabilizes Twist1 via K11/K63-linked deubiquitination to drive tumor metastasis in non-small cell lung cancer. [Abstract]

2025 Dec 30. PMID: 41469388
Cell Death Discov

Cysteine dioxygenase 1 attenuates the proliferation via inducing oxidative stress and integrated stress response in gastric cancer cells. [Abstract]

2022 Dec 16;8(1):493. PMID: 36526626
Cell Death Discov

Knockdown of METTL16 disrupts learning and memory by reducing the stability of MAT2A mRNA. [Abstract]

2022 Oct 28;8(1):432. PMID: 36307396
Cell Death Discov

PINK1 ameliorates acute-on-chronic liver failure by inhibiting apoptosis through mTORC2/AKT signaling. [Abstract]

2022 Apr 23;8(1):222. PMID: 35461334
Cell Death Discov

Long noncoding RNA SNHG1 silencing accelerates hepatocyte-like cell differentiation of bone marrow-derived mesenchymal stem cells to alleviate cirrhosis via the microRNA-15a/SMURF1/UVRAG axis. [Abstract]

2022 Feb 22;8(1):77. PMID: 35194023
Cell Death Discov

Loss of ID3 drives papillary thyroid cancer metastasis by targeting E47-mediated epithelial to mesenchymal transition. [Abstract]

2021 Aug 30;7(1):226. PMID: 34462424
Cell Death Discov

A redox probe screens MTHFD1 as a determinant of gemcitabine chemoresistance in cholangiocarcinoma. [Abstract]

2021 May 1;7(1):89. PMID: 33934113
Cell Rep

2026 Mar 27;45(4):117183. PMID: 41903135
Cell Rep

Targeting ZDHHC12-mediated PARP1 palmitoylation potentiates PARP inhibitor cytotoxicity. [Abstract]

2026 Jan 24;45(2):116910. PMID: 41581148
Cell Rep

A shear stress-responsive pathway in monocytes drives cardiopulmonary bypass-induced inflammation via spectrin/RAF1/store-operated calcium entry. [Abstract]

2026 Jan 22;45(2):116903. PMID: 41579376
Microbiol Res

Caspase-8 drove apoptosis of BMECs to promote neutrophil infiltration and DE205B clearance in meningitis. [Abstract]

2025 May 14:298:128223. PMID: 40408993
Cell Rep

NFE2-driven neutrophil polarization promotes pancreatic cancer liver metastasis progression. [Abstract]

2025 Jan 18;44(2):115226. PMID: 39827463
Cell Rep

Desuccinylation of TBK1 by SIRT5 regulates inflammatory response of macrophages in sepsis. [Abstract]

2024 Dec 13;43(12):115060. PMID: 39673708
Cell Rep

CRISPR screening identifies PRMT1 as a key pro-ferroptotic gene via a two-layer regulatory mechanism. [Abstract]

2024 Aug 22;43(9):114662. PMID: 39178116
Cell Rep

Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity. [Abstract]

2024 Mar 23;43(4):114003. PMID: 38527062
Cell Rep

GLUT1-mediated glucose import in B cells is critical for anaplerotic balance and humoral immunity. [Abstract]

2024 Feb 27;43(2):113739. PMID: 38340319
Clin Transl Med

Exosomal miR-3126-5p derived from cancer-associated fibroblasts facilitates glycolysis to accelerate NSCLC progression by targeting KLF13 to activate the SH2B1/IRS1 axis. [Abstract]

2025 Dec;15(12):e70554. PMID: 41410190
Br J Cancer

Fibroblast growth factor signals drive the metastatic behavior in small cell lung cancer. [Abstract]

2025 Dec 13. PMID: 41390896
Br J Cancer

The pronounced cytotoxic effects of chimeric antigen receptor T cells targeting B7-H3 in organoids and liver xenografts derived from colorectal cancer patients. [Abstract]

2025 Jul 28. PMID: 40721524
Neural Regen Res

Low-level expression of Cmyc in mature neurons: maintaining neuronal function and preventing neurodegeneration. [Abstract]

2025 Apr 29. PMID: 40313104
Antioxidants (Basel)

Fibroblast Upregulation of Vitamin D Receptor Represents a Self-Protective Response to Limit Fibroblast Proliferation and Activation during Pulmonary Fibrosis. [Abstract]

2023 Aug 18;12(8):1634. PMID: 37627629
J Cell Biol

Adapting plasma membrane for mitotic cell rounding through Aurora A phosphorylation of numb. [Abstract]

2025 Dec 1;224(12):e202412005. PMID: 41212116
Comput Biol Med

Liquid-liquid phase separation-related lncRNA prognostic signature and ZNF32-AS2 as a novel biomarker in hepatocellular carcinoma. [Abstract]

2024 Feb:169:107975. PMID: 38199212
EMBO Rep

UBE2O-mediated ubiquitylation directs cytoplasmic CTNNA1 to promote cell-to-ECM adhesions. [Abstract]

2025 Sep 22. PMID: 40983751
EMBO Rep

RNA-binding protein RBM47 stabilizes IFNAR1 mRNA to potentiate host antiviral activity. [Abstract]

2021 Aug 4;22(8):e52205. PMID: 34160127
Mol Ther Nucleic Acids

Bile acid accumulation induced by miR-122 deficiency in liver parenchyma promotes cancer cell growth in hepatocellular carcinoma. [Abstract]

2025 May 14;36(2):102560. PMID: 40520367
Antioxid Redox Signal

Sestrin 2 deficiency exacerbates noise-induced cochlear injury through inhibiting ULK1/Parkin-mediated mitophagy. [Abstract]

2023 Jan;38(1-3):115-136. PMID: 35708118
Cancer Cell Int

AURKA promotes angiogenesis in uveal melanoma via activation of the JAK2/STAT3/VEGFA signaling pathway. [Abstract]

2025 Jun 9;25(1):207. PMID: 40490746
Cancer Cell Int

Human colorectal cancer-derived carcinoma associated fibroblasts promote CD44-mediated adhesion of colorectal cancer cells to endothelial cells by secretion of HGF. [Abstract]

2019 Jul 24:19:192. PMID: 31367190
Environ Health

2025 Nov 28，XXXX(XXX).
Cell Biol Toxicol

Unraveling the molecular complexity: Wtap/Ythdf1 and Lcn2 in novel traumatic brain injury secondary injury mechanisms. [Abstract]

2024 Aug 7;40(1):65. PMID: 39110292
Transl Res

ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression. [Abstract]

2023 Sep:259:62-71. PMID: 37121538
Biochem Pharmacol

Repurposing Lamivudine: A novel therapeutic strategy for ischemic stroke targeting the glycolytic enzyme Pgk1. [Abstract]

2026 Jan;243(Pt 2):117529. PMID: 41213407
Biochem Pharmacol

Targeting TRAF6 inhibits cystogenesis in autosomal dominant polycystic kidney disease. [Abstract]

2025 Aug 9;242(Pt 2):117222. PMID: 40789372
Biochem Pharmacol

The deubiquitinase OTUD1 deubiquitinates TIPE2 and plays a protective role in sepsis-induced lung injury by targeting TAK1-mediated MAPK and NF-κB signaling. [Abstract]

2024 Jul 10:116418. PMID: 38996928
Biochem Pharmacol

The YY1-CPT1C signaling axis modulates the proliferation and metabolism of pancreatic tumor cells under hypoxia. [Abstract]

2024 Jul 10:116422. PMID: 38996932
Biochem Pharmacol

MICAL-L2, as an estrogen-responsive gene, is involved in ER-positive breast cancer cell progression and tamoxifen sensitivity via the AKT/mTOR pathway. [Abstract]

2024 May 9:225:116256. PMID: 38729448
Biochem Pharmacol

Berberine suppresses colon cancer cell proliferation by inhibiting the SCAP/SREBP-1 signaling pathway-mediated lipogenesis. [Abstract]

2020 Apr;174:113776. PMID: 31874145
Biochem Pharmacol

Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia. [Abstract]

2017 Mar 15:128:12-25. PMID: 28043811
Chem Biol Interact

2026 Apr 28:112112. PMID: 42061694
J Ethnopharmacol

Chebulinic acid shields Villin 1 from covalent attack to mitigate Euphorbia fischeriana enterotoxicity: A basis for safer anti-ascites therapy. [Abstract]

2025 Aug 18;353(Pt B):120435. PMID: 40835194
Food Funct

A novel method for exploration and prediction of the bioactive target of rice bran-derived peptide (KF-8) by integrating computational methods and experiments. [Abstract]

2024 Dec 9;15(24):11875-11887. PMID: 39529597
J Ethnopharmacol

Interaction of Bmal1 and eIF2α/ATF4 pathway was involved in Shuxie compound alleviation of circadian rhythm disturbance-induced hepatic endoplasmic reticulum stress. [Abstract]

2023 Aug 10:312:116446. PMID: 37019162
J Pathol

BIRC3 deficiency blocks the ubiquitination and degradation of GOT2 to impede antitumor immune responses in lung squamous cell carcinoma. [Abstract]

2025 Jul 21. PMID: 40690196
Commun Biol

Deoxynivalenol induces ferroptosis via inhibiting glycolysis-H3K18la-STEAP3 axis to promote ovary damage in piglets. [Abstract]

2025 Nov 20;8(1):1626. PMID: 41266595
Commun Biol

Pantothenic acid ameliorates hepatic fibrosis by targeting IGFBP6 to regulate the TGF-β/SMADs pathway. [Abstract]

2025 Jul 29;8(1):1127. PMID: 40730679
Commun Biol

m6A modification regulates cell proliferation via reprogramming the balance between glycolysis and pentose phosphate pathway. [Abstract]

2025 Mar 26;8(1):496. PMID: 40140553
Commun Biol

Therapeutic potential of microglial SMEK1 in regulating H3K9 lactylation in cerebral ischemia-reperfusion. [Abstract]

2024 Dec 26;7(1):1701. PMID: 39725685
Commun Biol

Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells. [Abstract]

2022 Aug 30;5(1):887. PMID: 36042378
Life Sci

KIR2DL4 promotes the proliferation of RCC cell associated with PI3K/Akt signaling activation. [Abstract]

2022 Mar 15:293:120320. PMID: 35063466
CNS Neurosci Ther

2026 Apr;32(4):e70879. PMID: 41968454
CNS Neurosci Ther

Angiotensin II Receptor-Associated Protein (AGTRAP) Enhances Glioma Cell Survival Through the IL-6/JAK2/STAT3 Pathway and Correlates With an Immunosuppressive Microenvironment. [Abstract]

2026 Feb;32(2):e70796. PMID: 41689202
Respir Res

Mechanical stress facilitates calcium influx and growth of alveolar epithelial cells via activation of the BDKRB1/Ca2+/CaMKII/MEK1/ERK axis. [Abstract]

2025 Apr 28;26(1):168. PMID: 40296124
Int J Oncol

Diverse roles of SERPINE1 in regulating cellular proliferation and invasion. [Abstract]

2026 May;68(5):58. PMID: 41823537
Int J Mol Sci

KIF18B Is Essential for Lung Adenocarcinoma Progression Through the E2F Transcriptional Network. [Abstract]

2026 Feb 13;27(4):1807. PMID: 41751942
Biol Direct

YTHDF2 promotes anaplastic thyroid cancer progression by activating the DDIT4/AKT/mTOR signaling pathway. [Abstract]

2024 Nov 26;19(1):122. PMID: 39593172
Int J Oncol

Lysine methyltransferase 5C increases the proliferation and metastatic abilities of clear cell renal cell carcinoma via aerobic glycolysis. [Abstract]

2024 Apr;64(4):45. PMID: 38426605
Int J Mol Sci

RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC. [Abstract]

2023 Sep 23;24(19):14476. PMID: 37833926
Int J Oncol

HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1. [Abstract]

2023 Apr;62(4):45. PMID: 36825600
Int J Oncol

Inhibiting the NF-κB pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer. [Abstract]

2020 Jul;57(1):161-170. PMID: 32377719
Bioorg Chem

Design and preclinical evaluation of lipophilicity-enhanced bicyclic peptide probes targeting Nectin4 Labeled with 68Ga/18F. [Abstract]

2026 Jul 5:175:109813. PMID: 41916034
mBio

A20 restricted PDCoV release through negative regulation of PANoptosis. [Abstract]

2026 Apr 8;17(4):e0008126. PMID: 41773863
Eur J Pharmacol

A comparative and critical assessment of in vitro strategies for the detection and generation of anastatic cell populations. [Abstract]

2026 Feb 28:1019:178708. PMID: 41771337
Reprod Biol Endocrinol

FTO regulates testosterone secretion in Leydig cells: insights into the role of m6A modifications and the therapeutic potential of hCG. [Abstract]

2025 Sep 24;23(1):121. PMID: 40993667
Int Immunopharmacol

VCPIP1 ameliorates sepsis-associated encephalopathy by promoting microglia autophagy via the PI3K/AKT/mTOR pathway. [Abstract]

2025 Aug 26:164:115417. PMID: 40865405
Int Immunopharmacol

Lipin1 ameliorates cognitive ability of diabetic encephalopathy via regulating Ca2+ transfer through mitochondria-associated endoplasmic reticulum membranes. [Abstract]

2025 Mar 26:150:114266. PMID: 39961213
Int Immunopharmacol

VCPIP1 negatively regulates NF-κB signaling pathways by deubiquitinating and stabilizing Erbin in MDP-stimulated macrophages. [Abstract]

2024 Nov 16;143(Pt 3):113622. PMID: 39550842
mBio

Regulation of the WNT-CTNNB1 signaling pathway by severe fever with thrombocytopenia syndrome virus in a cap-snatching manner. [Abstract]

2023 Dec 19;14(6):e0168823. PMID: 37882780
Int Immunopharmacol

MiR-223-3p attenuates radiation-induced inflammatory response and inhibits the activation of NLRP3 inflammasome in macrophages. [Abstract]

2023 Sep:122:110616. PMID: 37459784
World J Diabetes

SMAD specific E3 ubiquitin protein ligase 1 accelerates diabetic macular edema progression by WNT inhibitory factor 1. [Abstract]

2025 Mar 15;16(3):101328. PMID: 40093288
Biol Res

IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma. [Abstract]

2024 May 17;57(1):30. PMID: 38760850
Molecules

The Tumorigenic Effect of the High Expression of Ladinin-1 in Lung Adenocarcinoma and Its Potential as a Therapeutic Target. [Abstract]

2023 Jan 22;28(3):1103. PMID: 36770773
BMC Biol

ARv7 promotes the escape of prostate cancer cells from androgen deprivation therapy-induced senescence by mediating the SKP2/p27 axis. [Abstract]

2025 Feb 28;23(1):66. PMID: 40022149
Mol Pharm

Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer. [Abstract]

2024 Jul 1;21(7):3447-3458. PMID: 38843446
Clin Epigenetics

Epigenetic silencing of JAM3 promotes esophageal cancer development by activating Wnt signaling. [Abstract]

2022 Dec 2;14(1):164. PMID: 36461092
Mol Neurobiol

Umbilical Cord Mesenchymal Stromal Cell-Derived Extracellular Vesicles Transfer CD59 to Astrocytes to Alleviate Complement-Dependent Cytotoxicity. [Abstract]

2025 Nov 14;63(1):41. PMID: 41236660
Pharm Res

Investigation of the Binding Characteristics of Agonists and Various Antagonists Targeting Histamine 1 Receptor. [Abstract]

2025 Aug;42(8):1315-1329. PMID: 40760405
ACS Omega

Activation of the PERK Branch of the UPR as a Strategy for Improving Outcomes in Acute Ischemic Stroke. [Abstract]

2025 Apr 7;10(15):15461-15470. PMID: 40290914
Mol Neurobiol

GDF11 Regulates M1 and M2 Polarization of BV2 Microglial Cells via p38 MAPK Signaling Pathway. [Abstract]

2025 Jul;62(7):9290-9305. PMID: 40100492
Cancer Sci

FoxG1/BNIP3 axis promotes mitophagy and blunts cisplatin resistance in osteosarcoma. [Abstract]

2024 Aug;115(8):2565-2577. PMID: 38932521
FASEB J

2026 Apr 30;40(8):e71791. PMID: 41999223
Biochim Biophys Acta Mol Basis Dis

ANXA1 facilitates myeloid-derived suppressor cell infiltration in the non-small cell lung cancer immunomicroenvironment via the STING/NF-κB/CXCL5/CXCR2 signaling axis to enhance tumor progression. [Abstract]

2025 Oct;1871(7):167965. PMID: 40617338
FASEB J

NAD+ Metabolism Maintains the Homeostasis of Decidual Macrophages in Early Pregnancy. [Abstract]

2025 Jun 15;39(11):e70674. PMID: 40471104
Biochim Biophys Acta Mol Basis Dis

Serinc2 antagonizes pressure overload-induced cardiac hypertrophy via regulating the amino acid/mTORC1 signaling pathway. [Abstract]

2025 Jan 3:167650. PMID: 39756712
Biochim Biophys Acta Mol Basis Dis

LARP1, an RNA-binding protein, participates in ovarian cancer cell survival by regulating mitochondrial oxidative phosphorylation in response to the influence of the PI3K/mTOR pathway. [Abstract]

2024 Aug 5:167453. PMID: 39111634
Biochim Biophys Acta Mol Basis Dis

TRPV3 promotes sebocyte inflammation via transcriptional modulating TLR2 in acne. [Abstract]

2024 Apr 20;1870(5):167195. PMID: 38648901
Poult Sci

Establishment and characterization of an SV40 immortalized chicken intestinal epithelial cell line. [Abstract]

2023 Oct;102(10):102864. PMID: 37517361
J Cell Mol Med

SUMOylation mediates the disassembly of the Smad4 nuclear export complex via RanGAP1 in KELOIDS. [Abstract]

2023 Apr;27(8):1045-1055. PMID: 36916534
Stem Cell Rev Rep

Rab37 Promotes Endothelial Differentiation and Accelerates ADSC-Mediated Diabetic Wound Healing through Regulating Secretion of Hsp90α and TIMP1. [Abstract]

2023 May;19(4):1019-1033. PMID: 36627432
J Cell Mol Med

CD147 promotes progression of head and neck squamous cell carcinoma via NF-kappa B signaling. [Abstract]

2019 Feb;23(2):954-966. PMID: 30421493
Transl Oncol

UCHL1 promotes temozolomide resistance in glioblastoma by inhibiting the ubiquitination-mediated degradation of keratin 8. [Abstract]

2026 May:67:102728. PMID: 41861659
iScience

2025 Nov 30.
Transl Oncol

USP9X inhibits metastasis in pulmonary sarcomatoid carcinoma by regulating epithelial-mesenchymal transition, angiogenesis and immune infiltration. [Abstract]

2024 Jul 3:47:101950. PMID: 38964032
Transl Oncol

20-hydroxyecdysone suppresses bladder cancer progression via inhibiting USP21: A mechanism associated with deubiquitination and degradation of p65. [Abstract]

2024 Jul:45:101958. PMID: 38663220
J Neurochem

Beta-Arrestin2-Biased Activation by Pilocarpine Suppresses Microglial Inflammatory Response. [Abstract]

2025 Dec;169(12):e70334. PMID: 41457680
Sci Rep

KIF20A promotes cervical cancer progression by interacting with CLIP1. [Abstract]

2026 Mar 3;16(1):11838. PMID: 41776329
Oncol Rep

LRRC59 inhibits perk pathway‑induced apoptosis and promotes cell proliferation, migration and invasion in colorectal cancer cells. [Abstract]

2026 Jan;55(1):5. PMID: 41133451
Sci Rep

Unphosphorylated STAT1 binds to the BST2 transcription promoter, promoting increased AKBA anchoring on HPMECs to alleviate ARDS. [Abstract]

2025 Apr 30;15(1):15207. PMID: 40307322
Oncol Rep

The MyD88 inhibitor, ST2825, induces cell cycle arrest and apoptosis by suppressing the activation of the NF‑κB/AKT1/p21 pathway in pancreatic cancer. [Abstract]

2023 Aug;50(2):148. PMID: 37326109
J Biol Chem

Serine/threonine-protein kinase STK24 induces tumorigenesis by regulating the STAT3/VEGFA signaling pathway. [Abstract]

2023 Mar;299(3):102961. PMID: 36720310
Sci Rep

THBS1, a fatty acid-related metabolic gene, can promote the development of laryngeal cancer. [Abstract]

2022 Nov 5;12(1):18809. PMID: 36335208
Aging (Albany NY)

Inhibition of CDK9 attenuates atherosclerosis by inhibiting inflammation and phenotypic switching of vascular smooth muscle cells. [Abstract]

2021 Jun 8;13(11):14892-14909. PMID: 34102609
J Biol Chem

CTCF-binding element regulates ESC differentiation via orchestrating long-range chromatin interaction between enhancers and HoxA. [Abstract]

2021 Jan-Jun:296:100413. PMID: 33581110
J Biol Chem

Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint. [Abstract]

2021 Jan-Jun:296:100276. PMID: 33428943
Oncol Rep

TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2. [Abstract]

2021 Feb;45(2):523-534. PMID: 33416177
Aging

Long non-coding RNA SNHG12 promotes immune escape of ovarian cancer cells through their crosstalk with M2 macrophages. [Abstract]

2020 Sep 14;12(17):17122-17136. PMID: 32927431
Microbiol Spectr

2026 Apr 6;14(5):e0102825. PMID: 41940676
J Virol

Dissecting infectious bronchitis virus-induced host shutoff at the translation level. [Abstract]

2024 Jun 28:e0083024. PMID: 38940559
Dig Liver Dis

WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability. [Abstract]

2023 Jul;55(7):967-981. PMID: 36586770
Cell Signal

HDAC inhibitor enhances ferroptosis susceptibility of AML cells by stimulating iron metabolism. [Abstract]

2025 Jan 3:111583. PMID: 39756501
Biochim Biophys Acta Mol Cell Res

Suppression of GATA3 promotes epithelial-mesenchymal transition and simultaneous cellular senescence in human extravillous trophoblasts. [Abstract]

2024 Jun 3:119768. PMID: 38838858
Exp Mol Pathol

CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer. [Abstract]

2021 Dec:123:104704. PMID: 34624276
Mol Cell Biochem

Long non-coding RNA DANCR modulates osteogenic differentiation by regulating the miR-1301-3p/PROX1 axis. [Abstract]

2021 Jun;476(6):2503-2512. PMID: 33629241
Cell Signal

Hsa_circ_0069094 accelerates cell malignancy and glycolysis through regulating the miR-591/HK2 axis in breast cancer. [Abstract]

2021 Mar:79:109878. PMID: 33309838
Cell Signal

Activated CRH receptors inhibit autophagy by repressing conversion of LC3BI to LC3BII. [Abstract]

2019 Jun:58:119-130. PMID: 30849520
Development

Axin1 regulates tooth root development by inhibiting AKT1-mTORC1 activation and Shh translation in Hertwig's epithelial root sheath. [Abstract]

2024 Nov 1;151(21):dev202899. PMID: 39344774
Heliyon

METTL3/YTHDC1-mediated upregulation of LINC00294 promotes hepatocellular carcinoma progression. [Abstract]

2023 Nov 23;9(12):e22595. PMID: 38125436
Heliyon

Long noncoding RNA HOXC-AS3 remodels lipid metabolism and promotes the proliferation of transformed macrophages in the glioma stem cell microenvironment by regulating the hnRNPA1/CaM axis. [Abstract]

2023 Aug 9;9(8):e19034. PMID: 37609424
Heliyon

Lipofectamine 2000™ at transfection dose promotes EphA2 transcription in an HDAC4-dependent manner to reduce its cytotoxicity. [Abstract]

2022 Dec 6;8(12):e12118. PMID: 36544821
Viruses

ASFV MGF110-7L Inhibits eIF4G1 Expression via Endoplasmic Reticulum Stress to Block Host Translation. [Abstract]

2026 Feb 12;18(2):229. PMID: 41754572
Mol Med Rep

Integrative bioinformatics and experimental analysis reveals FRA1 as a key mediator of tubulointerstitial inflammation in lupus nephritis. [Abstract]

2026 Apr;33(4):103. PMID: 41614421
Cell Adh Migr

NCEH1 promotes breast cancer progression by regulating NRP1 and activating the TNF-α/NF-κB signalling pathway. [Abstract]

2026 Dec;20(1):2616948. PMID: 41592786
Orphanet J Rare Dis

Identification of NPR2 gene mutations affecting chondrocyte differentiation in short stature through JAK2-STAT5. [Abstract]

2025 Aug 1;20(1):392. PMID: 40750885
Viruses

Development and Evaluation of a Newcastle Disease Virus-like Particle Vaccine Expressing SARS-CoV-2 Spike Protein with Protease-Resistant and Stability-Enhanced Modifications. [Abstract]

2024 Dec 18;16(12):1932. PMID: 39772238
Exp Cell Res

Ketohexokinase-A deficiency attenuates the proliferation via reducing β-catenin in gastric cancer cells. [Abstract]

2024 Apr 16;438(1):114038. PMID: 38614422
Reprod Biomed Online

MicroRNA-122-5p alleviates endometrial fibrosis via inhibiting the TGF-β/SMAD pathway in Asherman's syndrome. [Abstract]

2023 Nov;47(5):103253. PMID: 37677924
Exp Cell Res

DEPTOR as a novel prognostic marker inhibits the proliferation via deactivating mTOR signaling pathway in gastric cancer cells. [Abstract]

2023 Apr 11;427(1):113598. PMID: 37054772
Exp Cell Res

Targeting CDK12 obviates the malignant phenotypes of colorectal cancer through the Wnt/β-catenin signaling pathway. [Abstract]

2023 Jul 1;428(1):113613. PMID: 37100369
J Gastroenterol Hepatol

IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation. [Abstract]

2026 Mar 12. PMID: 41820205
Toxicol Appl Pharmacol

Celastrol delays the progression of hepatocellular carcinoma by suppressing SLC1A5-mediated glutamine dependence. [Abstract]

2025 Dec 14:507:117690. PMID: 41401867
J Hepatocell Carcinoma

ZDHHC20 Activates AKT Signaling Pathway to Promote Cell Proliferation in Hepatocellular Carcinoma. [Abstract]

2024 Sep 18:11:1763-1775. PMID: 39309302
Toxicol Appl Pharmacol

A novel oleanolic acid derivative HA-19 ameliorates muscle atrophy via promoting protein synthesis and preventing protein degradation. [Abstract]

2019 Sep 1:378:114625. PMID: 31201822
BMC Cancer

A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia. [Abstract]

2018 Feb 13;18(1):182. PMID: 29439669
Front Oncol

Trans-Ancestry Mutation Landscape of Hepatoblastoma Genomes in Children. [Abstract]

2021 Apr 21:11:669560. PMID: 33968779
Stem Cells Int

Histone Demethylase KDM4C Is Required for Ovarian Cancer Stem Cell Maintenance. [Abstract]

2020 Aug 29:2020:8860185. PMID: 32908544
Mol Carcinog

Pregnane X Receptor Activation Induces Ferroptosis Resistance Through Upregulation of FSP1. [Abstract]

2025 Jul 17. PMID: 40674609
World J Clin Oncol

NOTCH1 combined with chemotherapy synergistically inhibits triple-negative breast cancer. [Abstract]

2025 Jun 24;16(6):106197. PMID: 40585842
Mol Carcinog

ALKBH5-Mediated m6A Modification of XBP1 Facilitates NSCLC Progression Through the IL-6-JAK-STAT3 Pathway. [Abstract]

2025 Jan;64(1):57-71. PMID: 39387829
J Cancer

SCAMP1 silencing inhibits proliferation by attenuating multiple pro-survival signaling pathways in gastric cancer. [Abstract]

2024 Sep 9;15(17):5762-5772. PMID: 39308691
Environ Toxicol

Exosomal miRNA-166-5p derived from G-MDSCs promotes proliferation by targeting ITM3E in colorectal cancer. [Abstract]

2024 Feb;39(2):803-814. PMID: 37792719
Mol Carcinog

Tandem mass tag (TMT) quantitative protein analysis-based proteomics and parallel reaction monitoring (PRM) validation revealed that MST4 accelerates osteosarcoma proliferation by increasing MRC2 activity. [Abstract]

2023 Sep;62(9):1338-1354. PMID: 37378424
J Cancer

CHAC2 promotes lung adenocarcinoma by regulating ROS-mediated MAPK pathway activation. [Abstract]

2023 May 8;14(8):1309-1320. PMID: 37283797
Environ Toxicol

Tumor-associated macrophages-derived exo-let-7a promotes osteosarcoma metastasis via targeting C15orf41 in osteosarcoma. [Abstract]

2023 Jun;38(6):1318-1331. PMID: 36919336
Naunyn Schmiedebergs Arch Pharmacol

2026 Apr 29. PMID: 42053796
Hum Cell

ZWINT down-regulated by miR-495-3p inhibited lung metastasis of breast cancer by blocking p38 MAPK signaling pathway activation. [Abstract]

2025 Oct 4;38(6):170. PMID: 41046283
Front Biosci (Landmark Ed)

Investigation Into the Pathogenesis of Type 2 Cardiorenal Syndrome via the ROS-TRPM2 Signaling Axis. [Abstract]

2025 Apr 30;30(5):27094. PMID: 40464493
Cancer Med

Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. [Abstract]

2019 Oct;8(13):5903-5915. PMID: 31426130
J Bioenerg Biomembr

METTL16-mediated m6A modification of LYRM2 drives breast cancer progression by inducing CD8+ T cell dysfunction via Glycolysis. [Abstract]

2026 Mar 18. PMID: 41849076
Arch Biochem Biophys

ApoM suppresses kidney renal clear cell carcinoma growth and metastasis via the Hippo-YAP signaling pathway. [Abstract]

2023 Jul 15:743:109642. PMID: 37211224
Acta Diabetol

High glucose mediates diabetic peripheral neuropathy by inducing Schwann cells apoptosis through the Dgkh/PKC-α signaling pathway. [Abstract]

2025 Jul 2. PMID: 40600984
Am J Cancer Res

ATXN3 deubiquitinates YAP1 to promote tumor growth. [Abstract]

2023 Sep 15;13(9):4222-4234. PMID: 37818078
Am J Cancer Res

Linc00662 m6A promotes the progression and metastasis of pancreatic cancer by activating focal adhesion through the GTF2B-ITGA1-FAK pathway. [Abstract]

2023 May 15;13(5):1718-1743. PMID: 37293163
R Soc Open Sci

Loss of miR-143 and miR-145 in condyloma acuminatum promotes cellular proliferation and inhibits apoptosis by targeting NRAS. [Abstract]

2018 Aug 29;5(8):172376. PMID: 30225000
J Biochem Mol Toxicol

Silencing of PODXL2 Modulates Cell Viability and Tumor Immune Microenvironment of Prostate Cancer and Involves PI3K/AKT Pathway Inactivation. [Abstract]

2025 Apr;39(4):e70210. PMID: 40152216
J Appl Toxicol

Inhibitory interaction of flavonoids with organic cation transporter 2 and their structure-activity relationships for predicting nephroprotective effects. [Abstract]

2023 Oct;43(10):1421-1435. PMID: 37057715
Genes (Basel)

Single Cell RNA-Seq Identifies Immune-Related Prognostic Model and Key Signature-SPP1 in Pancreatic Ductal Adenocarcinoma. [Abstract]

2022 Sep 29;13(10):1760. PMID: 36292645
Oncotargets Ther

G-MDSCs-Derived Exosomal miRNA-143-3p Promotes Proliferation via Targeting of ITM2B in Lung Cancer. [Abstract]

2020 Sep 30;13:9701-9719. PMID: 33061450
Onco Targets Ther

miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6. [Abstract]

2019 Jan 25:12:835-848. PMID: 30774371
Virus Res

PCBP2 inhibits antiviral innate immune responses via the MAVS-mediated signaling pathway in severe fever with thrombocytopenia syndrome. [Abstract]

2026 Mar:365:199699. PMID: 41638535
Vet Microbiol

IFITM3 restricts RABV infection through inhibiting viral entry and mTORC1- dependent autophagy. [Abstract]

2023 Sep:284:109823. PMID: 37392666
Virus Res

SARS-CoV-2 ORF3a positively regulates NF-κB activity by enhancing IKKβ-NEMO interaction. [Abstract]

2023 Apr 15:328:199086. PMID: 36894068
Vet Microbiol

Pseudorabies virus infection inhibits stress granules formation via dephosphorylating eIF2α. [Abstract]

2020 Aug:247:108786. PMID: 32768230
PLoS One

2026 Apr 9;21(4):e0341313. PMID: 41955245
Epigenomics

E2F1-driven cholesterol synthesis via the SND1/ACLY axis potentiates malignant progression in prostate cancer. [Abstract]

2026 Feb;18(2):155-168. PMID: 41588650
DNA Cell Biol

Gastric Cancer Cell-Derived Kynurenines Hyperactive Regulatory T Cells to Promote Chemoresistance via the IL-10/STAT3/BCL2 Signaling Pathway. [Abstract]

2022 Apr;41(4):447-455. PMID: 35353612
Cancer Manag Res

Is the Fixed Periodic Treatment Effective for the Tumor System without Complete Information?. [Abstract]

2021 Nov 30;13:8915-8928. PMID: 34876854
PLoS One

MicroRNA-193a inhibits breast cancer proliferation and metastasis by downregulating WT1. [Abstract]

2017 Oct 10;12(10):e0185565. PMID: 29016617
J Radiat Res Appl Sci

2026 Mar 5.
Cell Biochem Biophys

Elevated NDRG1 Expression Drives Oxaliplatin Chemoresistance in Bladder Cancer Cells by Promoting Homologous Recombination Repair and Inhibiting G2/M Arrest. [Abstract]

2025 Dec 10. PMID: 41369707
World J Surg Oncol

Mechanism of METTL14-mediated RAD21 mRNA epigenetic transcriptome modification in inhibiting thyroid cancer development. [Abstract]

2025 Nov 14;23(1):434. PMID: 41239449
Electrophoresis

Towards an Analytical Procedure Control Strategy for the Capillary Zone Electrophoresis Method for Monoclonal Antibodies: Alternatives for ε-Aminocaproic Acid and Triethylenetetramine. [Abstract]

2025 Sep 23. PMID: 40988426
Placenta

ARID1A recruits GATA2 to regulate the senescence of trophoblast cells under high-glucose condition. [Abstract]

2024 Dec:158:156-164. PMID: 39490111
Clin Transl Oncol

ADAM12 promotes gemcitabine resistance by activating EGFR signaling pathway and induces EMT in bladder cancer. [Abstract]

2023 May;25(5):1425-1435. PMID: 36512304
Anal Biochem

Quantification of 2-NBDG, a probe for glucose uptake, in GLUT1 overexpression in HEK293T cells by LC-MS/MS. [Abstract]

2021 Oct 15:631:114357. PMID: 34469746
Clin Transl Oncol

A novel tumor suppressor CECR2 down regulation links glutamine metabolism contributes tumor growth in laryngeal squamous cell carcinoma. [Abstract]

2021 Sep;23(9):1942-1954. PMID: 33826083
Gene

LncRNA GAS5 regulates apoptosis in ovarian cancer cells by regulating O-GlcNAcylation of GOLGA8B. [Abstract]

2026 May 15:991:150084. PMID: 41791436
Ann Hematol

Corilagin induces pyroptosis in AML cells by activating the TXNIP-caspase-3-GSDME pathway. [Abstract]

2026 Feb 11;105(3):107. PMID: 41670696
Amino Acids

IGF2BP1-mediated methylation of ABCA1 facilitates tumor progression by affecting cholesterol metabolism in lung adenocarcinoma. [Abstract]

2025 Aug 22;57(1):42. PMID: 40844715
Virology

ISG15 depletion enhances oHSV-1 replication and antitumor efficacy in oral squamous cell carcinoma. [Abstract]

2025 May:606:110504. PMID: 40121989
Virology

RTP4 restricts influenza A virus infection by targeting the viral NS1 protein. [Abstract]

2025 Jan 7:603:110397. PMID: 39798334
Gene

NLRP12 c.1382dup promotes the development of Crohn's disease through the ERK/NLRP3/ IL-1β pathway. [Abstract]

2024 Aug 22:931:148855. PMID: 39181275
PeerJ

Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner. [Abstract]

2022 Jun 6:10:e13535. PMID: 35694386
Vet Sci

Enhanced Porcine Reproductive and Respiratory Syndrome Virus Replication in Nsp4- or Nsp2-Overexpressed Marc-145 Cell Lines. [Abstract]

2025 Jan 13;12(1):52. PMID: 39852927
Thorac Cancer

SLC34A2 promotes cell proliferation by activating STX17-mediated autophagy in esophageal squamous cell carcinoma. [Abstract]

2024 May 8. PMID: 38720472
J Mol Histol

Knockdown of circ_0000372 elevates PD-L1 level through sponging miR-488-3p to restrain cell viability, motility and immune escape in gastric cancer. [Abstract]

2025 Sep 13;56(5):312. PMID: 40944812
Oncol Lett

Overexpression of miR‑424‑5p reduces cisplatin resistance by downregulating SMURF1 in gastric cancer. [Abstract]

2025 Jan 15;29(3):143. PMID: 39850720
Oncol Lett

EGFR mediates epithelial‑mesenchymal transition through the Akt/GSK-3β/Snail signaling pathway to promote liver cancer proliferation and migration. [Abstract]

2023 Dec 18;27(2):59. PMID: 38192662
Biochem Biophys Res Commun

TRABID targets DDB2 for deubiquitination to promote proliferation of hepatocellular carcinoma cells. [Abstract]

2022 Oct 15:625:23-30. PMID: 35944360
Biochem Biophys Res Commun

TRAM2 promotes the malignant progression of glioma through PI3K/AKT/mTOR pathway. [Abstract]

2022 Jan 1:586:34-41. PMID: 34826698
Biochem Biophys Res Commun

The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma. [Abstract]

2021 Nov 26:580:48-55. PMID: 34624569
Mol Genet Genomics

Buparlisib induces eukaryotic elongation factor-2 expression to cause treatment failure for lung cancer cells. [Abstract]

2026 Jan 31;301(1):26. PMID: 41619002
Liver Res

2025 Sep 22.
Cancer Invest

Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss. [Abstract]

2021 May;39(5):423-434. PMID: 33683975
Ir J Med Sci

ESPN promotes proliferation, invasion and immune escape of gastric cancer cells by regulating AKT/NF-κB pathway. [Abstract]

2026 Mar 28. PMID: 41903046
Am J Transl Res

Cyclooxygenase-2 expressed hepatocellular carcinoma induces cytotoxic T lymphocytes exhaustion through M2 macrophage polarization. [Abstract]

2021 May 15;13(5):4360-4375. PMID: 34150019
Am J Transl Res

Differentiated embryonic chondrocyte-expressed gene 1 promotes temozolomide resistance by modulating the SP1-MGMT axis in glioblastoma. [Abstract]

2021 Apr 15;13(4):2331-2349. PMID: 34017393
Neurol Res

Peroxidasin promotes malignant progression by enhancing glycolytic metabolism in glioblastoma through the regulation of LDHA. [Abstract]

2026 Mar 17:1-15. PMID: 41842610
Adv Tradit Med

2025 Aug 8.
STAR Protoc

Identification of phosphorylation site on PARP1 mediating its cytosolic translocation in virus-infected HeLa cells. [Abstract]

2022 Nov 2;3(4):101808. PMID: 36386864
STAR Protoc

Protocol for inducible piggyBac transposon system for efficient gene overexpression in human pluripotent stem cells. [Abstract]

2022 Apr 13;3(2):101296. PMID: 35496784
Indian J Pharm Educ

2024 Jun 21.
Bull Cancer

Melatonin promotes differentiation and apoptosis of AML1-ETO-positive cells. [Abstract]

2023 Apr;110(4):342-351. PMID: 36863921
New York University

2026.
SSRN

2026 Mar 2.
Extracell Vesicle

2026 Jan 30.
medRxiv

2025 Nov 28.
SSRN

2025 Dec 2.
Res Sq

2025 Dec 25.
Purdue University

2025.
bioRxiv

2025 Nov 6.
SSRN

2025 Oct 9.
SSRN

2025 Sep 16.
bioRxiv

2025 Aug 17.
bioRxiv

Herpes simplex virus-1 fluidizes the nucleus enabling condensate formation. [Abstract]

2025 Jun 21:2025.06.20.660750. PMID: 40667204
Research Square Print

2025 May 28.
bioRxiv

2025 April 10.
SSRN

2025 Jan 24.
bioRxiv

2025 March 24.
University of Bonn

2025 Feb.
Res Sq

2024 Nov 07.
bioRxiv

AMPK agonism optimizes the in vivo persistence and anti-leukemia efficacy of chimeric antigen receptor T cells. [Abstract]

2024 Sep 29:2024.09.26.615290. PMID: 39386600
bioRxiv

2024 August 30.
Cell Mol Biol (Noisy-le-grand)

MicroR-1199-5p targeting SRD5A2 promotes the biological behavior and EMT of hypospadias cells. [Abstract]

2024 Jun 5;70(6):122-128. PMID: 38836672
bioRxiv

2024 Mar 29.
Research Square Preprint

2023 Nov 25.
bioRxiv

2023 Oct 4.
Research Square Preprint

2023 Sep 27.
bioRxiv

2023 Jun 17.
Hum Cell

PSMD4 drives progression of hepatocellular carcinoma via Akt/COX2 pathway and p53 inhibition. [Abstract]

2023 Sep;36(5):1755-1772. PMID: 37336868
bioRxiv

Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer. [Abstract]

2023 Mar 31:2023.03.29.534783. PMID: 37034813
Research Square Print

2023 Mar 15.
Research (Wash D C)

CNS Organoid Surpasses Cell-Laden Microgel Assembly to Promote Spinal Cord Injury Repair. [Abstract]

2022 Aug 3:2022:9832128. PMID: 36061824
Dis Markers

hsa_circ_0003176 Suppresses the Progression of Non-Small-Cell Lung Cancer via Regulating miR-182-5p/RBM5 Axis. [Abstract]

2022 Sep 23;2022:8402116. PMID: 36193508
Research Square Print

2022 Aug.
Research Square Preprint

2022 May.
bioRxiv

April 11, 2022.
Research Square Preprint

2022 Jan.
Research Square Preprint

2021 Nov.
Research Square Preprint

2021 Aug.
SSRN

2021 Jun.
Evid Based Complement Alternat Med

Compound Phyllanthus urinaria L Inhibits HBV-Related HCC through HBx-SHH Pathway Axis Inactivation. [Abstract]

2019 Mar 24:2019:1635837. PMID: 31019539

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (212.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1 mg/mL (2.12 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1208 mL

10.6042 mL

21.2085 mL

5 mM

0.4242 mL

2.1208 mL

4.2417 mL

10 mM

0.2121 mL

1.0604 mL

2.1208 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (10.60 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (10.60 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (10.60 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (277 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92. [Content Brief]

[2]. Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28(5):1176-82. [Content Brief]

[3]. Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6(4):275-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.1208 mL	10.6042 mL	21.2085 mL	53.0211 mL
DMSO	5 mM	0.4242 mL	2.1208 mL	4.2417 mL	10.6042 mL
	10 mM	0.2121 mL	1.0604 mL	2.1208 mL	5.3021 mL
	15 mM	0.1414 mL	0.7069 mL	1.4139 mL	3.5347 mL
	20 mM	0.1060 mL	0.5302 mL	1.0604 mL	2.6511 mL
	25 mM	0.0848 mL	0.4242 mL	0.8483 mL	2.1208 mL
	30 mM	0.0707 mL	0.3535 mL	0.7069 mL	1.7674 mL
	40 mM	0.0530 mL	0.2651 mL	0.5302 mL	1.3255 mL
	50 mM	0.0424 mL	0.2121 mL	0.4242 mL	1.0604 mL
	60 mM	0.0353 mL	0.1767 mL	0.3535 mL	0.8837 mL
	80 mM	0.0265 mL	0.1326 mL	0.2651 mL	0.6628 mL
	100 mM	0.0212 mL	0.1060 mL	0.2121 mL	0.5302 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Puromycin

398 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Puromycin

Anti-Infection Compound Library

Natural Product Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Alkaloids Library

Antiparasitic Compound library

Microbial Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Nephrotoxicity Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Puromycin

Voir tous les produits spécifiques à Isoform Antibiotic

Voir tous les produits spécifiques à Isoform Parasite

Activité biologique

Chemical Information

Publications (398)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Puromycin

Anti-Infection Compound Library

Natural Product Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Alkaloids Library

Antiparasitic Compound library

Microbial Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Nephrotoxicity Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Puromycin

Voir tous les produits spécifiques à Isoform Antibiotic

Voir tous les produits spécifiques à Isoform Parasite

Activité biologique

Chemical Information

Publications (398)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Puromycin Related Classifications

Cat. No.: HY-B1743